These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23403415)

  • 1. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder.
    Hope S; Ueland T; Steen NE; Dieset I; Lorentzen S; Berg AO; Agartz I; Aukrust P; Andreassen OA
    Schizophr Res; 2013 Apr; 145(1-3):36-42. PubMed ID: 23403415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia.
    Hope S; Dieset I; Agartz I; Steen NE; Ueland T; Melle I; Aukrust P; Andreassen OA
    J Psychiatr Res; 2011 Dec; 45(12):1608-16. PubMed ID: 21889167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent increase in TNF and IL-1 markers in severe mental disorders suggests trait-related inflammation: a one year follow-up study.
    Mørch RH; Dieset I; Faerden A; Hope S; Aas M; Nerhus M; Gardsjord ES; Haram M; Falk RS; Joa I; Morken G; Agartz I; Aukrust P; Djurovic S; Melle I; Ueland T; Andreassen OA
    Acta Psychiatr Scand; 2017 Oct; 136(4):400-408. PubMed ID: 28815548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls.
    Hope S; Hoseth E; Dieset I; Mørch RH; Aas M; Aukrust P; Djurovic S; Melle I; Ueland T; Agartz I; Ueland T; Westlye LT; Andreassen OA
    Schizophr Res; 2015 Jul; 165(2-3):188-94. PubMed ID: 25956633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory evidence for the psychosis continuum model.
    Mørch RH; Dieset I; Færden A; Hope S; Aas M; Nerhus M; Gardsjord ES; Joa I; Morken G; Agartz I; Aukrust P; Djurovic S; Melle I; Ueland T; Andreassen OA
    Psychoneuroendocrinology; 2016 May; 67():189-97. PubMed ID: 26923849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor.
    Hope S; Melle I; Aukrust P; Steen NE; Birkenaes AB; Lorentzen S; Agartz I; Ueland T; Andreassen OA
    Bipolar Disord; 2009 Nov; 11(7):726-34. PubMed ID: 19839997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein.
    Dieset I; Hope S; Ueland T; Bjella T; Agartz I; Melle I; Aukrust P; Røssberg JI; Andreassen OA
    Schizophr Res; 2012 Sep; 140(1-3):169-74. PubMed ID: 22817875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission.
    Tsai SY; Chung KH; Huang SH; Chen PH; Lee HC; Kuo CJ
    Bipolar Disord; 2014 Dec; 16(8):800-8. PubMed ID: 25130211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders.
    Gohar SM; Dieset I; Steen NE; Mørch RH; Iversen TS; Steen VM; Andreassen OA; Melle I
    Eur Arch Psychiatry Clin Neurosci; 2019 Oct; 269(7):795-802. PubMed ID: 29721726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder.
    Tsai SY; Chung KH; Wu JY; Kuo CJ; Lee HC; Huang SH
    J Affect Disord; 2012 Jan; 136(1-2):110-116. PubMed ID: 21962564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between altered brain morphology and elevated peripheral endothelial markers--implications for psychotic disorders.
    Dieset I; Haukvik UK; Melle I; Røssberg JI; Ueland T; Hope S; Dale AM; Djurovic S; Aukrust P; Agartz I; Andreassen OA
    Schizophr Res; 2015 Feb; 161(2-3):222-8. PubMed ID: 25433965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis.
    Comabella M; Julià E; Tintoré M; Brieva L; Téllez N; Río J; López C; Rovira A; Montalban X
    J Neurol; 2008 Aug; 255(8):1136-41. PubMed ID: 18484235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble TNF-alpha receptor and IL-1 receptor antagonist elevation in BAL in active pulmonary TB.
    Tsao TC; Li L; Hsieh M; Liao S; Chang KS
    Eur Respir J; 1999 Sep; 14(3):490-5. PubMed ID: 10543265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.
    Goldsmith DR; Rapaport MH; Miller BJ
    Mol Psychiatry; 2016 Dec; 21(12):1696-1709. PubMed ID: 26903267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation in psychotic disorders: a population-based study.
    Suvisaari J; Loo BM; Saarni SE; Haukka J; Perälä J; Saarni SI; Viertiö S; Partti K; Lönnqvist J; Jula A
    Psychiatry Res; 2011 Sep; 189(2):305-11. PubMed ID: 21798602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of interleukin-1 receptor antagonist (IL-1ra) and severity of illness in patients with burns.
    Endo S; Inada K; Yamada Y; Kasai T; Takakuwa T; Nakae H; Kamei Y; Shimamura T; Suzuki T; Taniguchi S; Yoshida M
    J Med; 1996; 27(1-2):57-71. PubMed ID: 8863178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The enhanced plasma levels of soluble tumor necrosis factor receptors (sTNF-R1; sTNF-R2) and interleukin-10 (IL-10) in patients suffering from chronic heart failure are reversed in patients treated with beta-adrenoceptor antagonist.
    Loppnow H; Werdan K; Werner C
    Auton Autacoid Pharmacol; 2002 Apr; 22(2):83-92. PubMed ID: 12568125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevation of serum soluble tumour necrosis factor (TNF) receptor and IL-1 receptor antagonist levels in bronchial asthma.
    Yoshida S; Hashimoto S; Nakayama T; Kobayashi T; Koizumi A; Horie T
    Clin Exp Immunol; 1996 Oct; 106(1):73-8. PubMed ID: 8870701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis.
    Muzaffer MA; Dayer JM; Feldman BM; Pruzanski W; Roux-Lombard P; Schneider R; Laxer RM; Silverman ED
    J Rheumatol; 2002 May; 29(5):1071-8. PubMed ID: 12022325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.